RNA therapeutics firm Chimeron Bio has collaborated with George Mason University’s National Center for Biodefense and Infectious Diseases (NCBID) to develop a Covid-19 vaccine candidate.
The vaccine will be developed using Chimeron Bio’s ChaESAR self-amplifying RNA technology, and supported by Mason’s expertise and Biomedical Research Laboratory (BRL) for screening the company’s vaccine pipeline.
George Mason University’s College of Science systems biology associate professor Dr Aarthi Narayanan said: “Our collaborators at Chimeron Bio have a strong commitment to pursuing innovative, personalised treatments which aligns well with our research philosophy – exploring innovative approaches to solve big global problems.” ChaESAR is a